参考文献/References:
[1] 肿瘤核素靶向治疗的研究进展[J].国际放射医学核医学杂志,2008,32(4):206-208.
[2] Witzig TE,Gordon LI,Cabanillas F,et al.Randomized controlled trial of yttrium-90-labeled britumomab tiuxetan radioimmunothera-py versus rituximab immunotherapy for patients with relapsed or re-fractory low-grade,follicular,or transformed B-cell non-Hodgkin’s lymphoma[J].J Clin Oncol,2002,20(10):2453-2463.
[3] Alcindor T,Witzig TE.Radioimmunotherapy with yttrium-90 ibri-tumomab tiuxetan for patients with relapsed CD20+B-cell non-Hodgkin7 slymphoma[J].Curr Treat Options Oncol,2002,3(4):275-282.
[4] Horning SJ,Younes A,Jain V,et al.Efficacy and safety of tositu-momab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma,progressive after rituximab[J].J Clin Oncol,2005,23(4):712-719.
[5] Kaminski MS,Zelenetz AD,Press OW,et al.Pivotal study of io-dine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas[J].J Clin Oncol,2001,19(19):3918-3928.
[6] Chen SL, Yu LK,Jiang CY,et al.Pivotal study of iodine-131-la-beled chimeric tumor necrosis treatment radioimmunotherapy inpatients with advanced lung cancer[J].J Clin Oncol,2005,23(7):1538-1547.
[7] Chen ZN,Mi L, Xu J,et al.Targeting radioimmunotherapy of hepa-tocellular carcinoma with Iodine(I-131)metuximab injection:Clin-ical phase I/Ⅱ trials[J].Int J Radiat Oncol Biol Phys,2006,65(2):435-444.
[8] W uL, YangYF,Ge NJ,et al.Hepatic artery injection of 131I-labelledmetuximab combined with chemoembolization for intermediatehepatocellular carcinoma:a prospective nonrandomized study[J].Eur J Nucl Med Mol Imaging,2012,39(8):1306-1315.
[9] Liersch T,Meller J,Kulle B,et al.Phase Ⅱ trial of carcinoembryon-ic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver:five-year safety and efficacy results[J].J Clin Oncol,2005,23(27):6763-6770.
[10] Han S,Jin G,Wang L,et al.The role of PAM4 in the management of pancreatic cancer:diagnosis,radioimmunodetection,and ra-dioimmunotherapy[J/OL].J Immunol Res,2014,2014:268479[2014-12-10].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003775.
[11] 冯春玲.放射免疫治疗中载体的研究进展[J].国际放射医学核医学杂志,2007,31(2):77-79.
[12] Sahoo SK, Parveen S, Panda JJ.The present and future of nanotech-nology in human health care[J].Nanomedicine,2007,3(1):20-31.
[13] Gobin AM,Lee MH,Halas NJ,et al.Nearinfrared resonant nanoshells for combined opticalimaging and photothermal cancer therapy[J].Nano Lett,2007,7(7):1929-1934.
[14] Hong H,Zhang Y,Sun JT,et al.Molecular imaging and therapy of cancer with radiolabeled nanoparticles[J].Nano Today,2009,4(5):399-413.
[15] Alberti C.From molecular imaging in preclinical/clinical oncology to theranostic applications in targeted tumor therapy[J].Eur Rev Med Pharmacol Sci,2012,16(14):1925-1933.
[16] Baum RP,Kulkarni HR.THERANOSTICS:from molecular imag-ing using Ga-68 labeled tracers and PET/CT to personalized ra-dionuclide therapy-the bad Berka experience[J].Theranostics,2012,2(5):437-447.
[17] Cremonesi M,Ferrari M,Bodei L,et al.Dosimetry in peptide ra-[30] dionuclide receptor therapy:a review[J].J Nucl Med,2006,47(9):1467-1475.
[18] Reubi JC,Schar JC,Waser B,et al.Affinity profiles for human so-matostatin receptor subtypes SST1-SST5 of somatostatin radiotrac-ers selected for scintigraphic and radiotherapeutic use[J].Eur J Nucl Med,2000,27(3):273-282.
[19] Waldherr C,Pless M,Maecke HR,et al.Tumor response and clini-cal benefit in neuroendocrine tumors after 7.4 GBq (90)Y-D0TAT0C[J].J Nucl Med,2002,43(5):610-616.
[20] Kwekkeboom DJ,de Herder WW,Kam BL,et al.Treatment with the radiolabeled somatostatin analog[177Lu-D0TA0,Tyr3] octreo-tate:toxicity,efficacy,and survival[J].J Clin Oncol,2008,26(13):2124-2130.
[21] Imhof A,Brunner P,Marincek N,et al.Response,survival,andlong-term toxicity after therapy with the radiolabeled somatostati-Nanalogue[99Y-DOTAJ-TOC in metastasized neuroendocrine cancers[J].J Clin Oncol,2011,29(17):2416-2423.
[22] Jurcic JG,Larson SM,Sgouros G,et al.Targeted alpha particle im-munotherapy for myeloidleukemia[J].Blood,2002,100(4):1233-1239.
[23] Nilsson S,Franzen L,Parker C,et al.Bone-targeted radium-223 in symptomatic,hormonerefractoryprostate cancer:a randomised,multicentre,placebo-controlled phase Ⅱ study[J].Lancet Oncol,2007,8(7):587-594.
[24] Zalutsky MR,Reardon DA,Akabani G,et al.Clinical experience with alpha-particle emitting 211At:treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6[J].J Nucl Med,2008,49(1):30-38.
[25] Nayak T,Norenberg J,Anderson T,et al.A comparison of high-ver-sus low-linear energy transfer somatostatin receptortargeted ra-dionuclide therapy in vitro[J].Can Biother Radio,2005,20(1):52-57.
[26] Nayak TK,Norenberg JP,Anderson TL,et al.Somatostatin-recep-tor-targeted alpha-emitting Bi-213 is therapeutically more effective than beta-emitting Lu-177 in human pancreatic adenocarcinoma cells[J].Nucl Med Biol,2007,34(2):185-193.
[27] Kratochwil C,Giesel FL,Bruchertseifer F,et al.213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation:a first-in-hu-man experience[J].Eur J Nucl Med Mol Imaging,2014,41(11):2106-2119.
[28] de Jong M,Breeman WA,Valkema R,et al.Combination radionu-clide therapy using 177Lu-and 90Y-labeled somatostatin analogs[J].J Nucl Med,2005,46(Suppl 1):13S-17S.
[29] Kunikowska J,Królicki L,Hubalewska-Dydejczyk A,et al.Clinicalresults of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE:which is a bettertherapy option?[J].Eur J Nucl Med Mol Imaging,2011,38(10):1788-1797.
[30] Villard L,Romer A,Marincek N,et al.Cohort study of somato-statin-based radiopeptide therapy with[(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus[(177)Lu-DOTA]-TOC in neuroendocrine cancers[J].J Clin Oncol,2012,30(10):1100-1106.
[31] Sawada N,Ishikawa T,Sekiguchi F,et al.X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda)in human cancer xenografts[J].Clin Cancer Res,1999,5(10):2948-2953.
[32] Rich TA,Shepard RC,Mosley ST.Four decades of continuing in-novation with fluorouracil:current and future approaches to fluo-rouracil chemoradiation therapy[J].J Clin Oncol,2004,22(11):2214-2232.
[33] van Essen M,Krenning EP,Kam BL,et al.Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroen-docrine tumours[J].Eur J Nucl Med Mol Imaging,2008,35(4):743-748.
[34] Claringbold PG,Brayshaw PA,Price R A,et al.Phase Ⅱ study ofradiopeptide 177 Lu-octreotate and capecitabine therapy of progres-sive disseminated neuroendocrine tumours[J].Eur J Nucl Med MolImaging,2011,38(2):302-311.
[35] Nayak TK,Atcher RW,Prossnitz ER,et al.Enhancement of somatostatin-receptor-targeted (177) Lu-[DOTA(0)-Tyr(3)]-oc-treotide therapy by gemcitabine pretreatment-mediated receptor uptake,up-regulation and cell cycle modulation[J].Nucl Med Biol,2008,35(6):673-678.
[36] Kaemmerer D,Prasad V,Daffner W,et al.Neoadjuvant peptide re-ceptor radionuclide therapy for an inoperable neuroendocrine pan-creatic tumor[J].World J Gastroenterol,2009,15(46):5867-5870.
[37] Stoeltzing O,Loss M,Huber E,et al.Staged surgery with neoadju-vant (90) Y-DOTATOC therapy for down-smng synchronous bilob-ular hepatic metastases from a neuroendocrine pancreatic tumor[J].Langenbecks Arch Surg,2010,395(2):185-192.
[38] Breeman WA,Mearadji A,Capello A,et al.Anti-tumor effect and increased survival after treatment with[177Lu-DOTAO,Tyr3] octreo-tate in a rat liver micrometastases model[J].Int J Cancer,2003,104(3):376-379.
[39] Ginj M,Zhang H,Waser B,et al.Radiolabeled somatostatin recep-tor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors[J].Proc Natl Acad Sci USA,2006,103(44):16436-16441.
[40] Cescato R,Waser B,Fani M,et al.Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human can-cers in vitro[J].J Nucl Med,2011,52(12):1886-1890.
[41] Wild D,Fani M,Behe M,et al.First clinical evidence that imaging with somatostatinreceptor antagonists is feasible[J].J Nucl Med,2011,52(9):1412-1417.
[42] Wild D,Fani M,Fischer R,et al.Comparison of somatostatin re-ceptor agonist and antagonist for peptide receptor radionuclide therapy:a pilot study[J].J Nucl Med,2014,55(8):1248-1252.
[43] Zhu ZH,Miao WB,Li QW,et al.99mTc-3PRGD2 for integrin recep-tor imaging of lung cancer:a multicenter study[J].J Nucl Med,2012,53(5):716-722.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[4]王立凯,黄丽娟,潘学继,等.人附睾蛋白4单克隆抗体与免放试剂盒的制备及其对卵巢癌诊断的临床价值探讨[J].国际放射医学核医学杂志,2016,40(3):183.[doi:10.3760/cma.j.issn.1673-4114.2016.03.005]
Wang Likai,Huang Lijuan,Pan Xueji,et al.Preparation of monoclonal antibodies and immunoradiometric assay kit against human epididymis protein 4 and its clinical value in diagnosis of ovarian cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):183.[doi:10.3760/cma.j.issn.1673-4114.2016.03.005]
[5]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[6]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[7]汪文霞,兰晓莉,张永学.HER2的表达及其分子影像的研究进展[J].国际放射医学核医学杂志,2016,40(5):363.[doi:10.3760/cma.j.issn.1673-4114.2016.05.007]
Wang Wenxia,Lan Xiaoli,Zhang Yongxue.Research and development of HER2 expression molecular imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):363.[doi:10.3760/cma.j.issn.1673-4114.2016.05.007]
[8]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[9]任佳忠,李永梅,刘岩,等.99Tcm-MDP骨显像胸部异常放射性摄取的原因分析[J].国际放射医学核医学杂志,2016,40(6):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
Jiazhong,Li Yongmei,Liu Yan,et al.Reasons for the abnormal 99Tcm-MDP uptake in the thoracic tissue on bone scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
[10]马彦云,张辉.磁共振体素内不相干运动扩散加权成像的原理及应用进展[J].国际放射医学核医学杂志,2016,40(6):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
Ma Yanyun,Zhang Hui.The basic principle and application progress of intravoxel incoherent motion imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
[11]郭艾楠,魏玲格,傅鹏.131I-肿瘤细胞核人鼠嵌合单克隆抗体治疗实体瘤的研究进展[J].国际放射医学核医学杂志,2013,37(2):120.[doi:10.3760/cma.j.issn.1673-4114.2013.02.015]
GUO Ai-nan,WEI Ling-ge,FU Peng.Advances on the treatment of solid tumor by 131I labeled mouse-human chimeric tumor necrosis therapy monoclanal antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):120.[doi:10.3760/cma.j.issn.1673-4114.2013.02.015]